MAP2K7 and cancer: Synergistic effects of HDM2 antagonist AMG-232 with many PI3K/Akt/mTOR and Ras/Raf/MEK/MAPK inhibitors were also reported on twenty different human cancer cell lines and in RKO tumor xenograft in vivo experiments [79].